OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose